Results 41 to 50 of about 1,444,670 (278)
Cardiac Myosin Inhibition for Treatment of LVOT Obstruction in a Patient With Severe AS
JACC: Case ReportsAortic stenosis and obstructive hypertrophic cardiomyopathy are common conditions. When both are present in the same patient, the management can be challenging.
Ronald H. Wharton, MD +4 more
doaj +1 more source
Distinct gene expression patterns in skeletal and cardiac muscle are dependent on common regulatory sequences in the MLC1/3 locus [PDF]
, 1996 The myosin light-chain 1/3 locus (MLC1/3) is regulated by two promoters and a downstream enhancer element which produce two protein isoforms in fast skeletal muscle at distinct stages of mouse embryogenesis. We have analyzed the expression of transcripts
McGrew, M J; id_orcid +5 more
core
Advanced Materials Interfaces, EarlyView.Fibrin–gelatin hydrogels functionalized with reduced graphene oxide create a mechanically stable and bioactive 3D environment for engineered cardiac tissue. The composite matrix promotes endothelial lumen formation, enhances sarcomeric protein expression, and increases contractile performance of embedded cardiomyocytes.
Christoph Kuckelkorn +5 more
wiley +1 more source
Cardiac Myosin Inhibitors in Hypertrophic Cardiomyopathy: From Sarcomere to Clinic
International Journal of Molecular SciencesHypertrophic cardiomyopathy (HCM) is a primary myocardial disease characterized by unexplained left ventricular hypertrophy, often resulting from pathogenic variants of sarcomeric protein genes. Conventional treatments, such as the use of beta blockers or calcium channel blockers, focus on symptomatic control but do not address the underlying ...
Kazufumi Nakamura +7 more
openaire +4 more sources
Journal of the American Heart Association: Cardiovascular and Cerebrovascular DiseaseBackground Aficamten, a novel cardiac myosin inhibitor, reversibly reduces cardiac hypercontractility in obstructive hypertrophic cardiomyopathy. We present a prespecified analysis of the pharmacokinetics, pharmacodynamics, and safety of aficamten in ...
Caroline J. Coats +35 more
doaj +1 more source
Advanced Science, EarlyView.The pre‐regenerative vascular niche (PVN) is essential for nerve repair, yet its endothelial blueprint remains unclear. We identified angiogenic ECs (AECs) as the dominant pre‐regenerative subset and found that antler blood–derived exosomes (AB‐EXO) promote repair via IMP3.
Jinsheng Huang +11 more
wiley +1 more source
Frontiers in Cardiovascular MedicineMavacamten is a first-in-class cardiac myosin ATPase inhibitor, approved by the United States Food and Drug Administration for the treatment of hypertrophic cardiomyopathy with obstructive physiology (oHCM).
Daniel Seung Kim +92 more
doaj +1 more source
Progress in New Therapies Targeting the Pathogenesis of Cardiomyopathywith Hypertrophic Phenotype
罕见病研究, 2023 Hypertrophic cardiomyopathy (HCM) is cardiomyopathy with a clinical phenotype of cardiac hypertrophy. The etiology includes genetically defective encoding sarcomeres, congenital metabolic diseases such as lysosomal storage diseases, systemic amyloidosis ...
LIU Yanbo, TIAN Zhuang, ZHANG Shuyang
doaj +1 more source
The clinical characteristics of families with hypertrophic cardiomyopathy associated with mutations of cardiac myosin binding protein C [PDF]
, 2010 Introduction: Mutations in cardiac myosin binding protein-C (MYBPC3), the most common genetic cause of hypertrophic cardiomyopathy (HCM), have been reported to cause a comparatively benign and late-onset form of the disease with incomplete penetrance ...
Page, S.P.
core
Advanced Science, EarlyView.This study developed an efficacy assessment platform that integrates patient‐derived gastric cancer organoids, atomic force microscopy (AFM)‐based nanomechanical vibration detection, deep learning analysis, and organoid mechanical modeling. It detects picomolar drug effects within 0.1 s signal, achieves 97% classification accuracy, and offers non ...
Ting Zhang +10 more
wiley +1 more source